CG Oncology

We have seen exciting results with the novel investigational oncolytic immunotherapy, cretostimogene grenadenorepvec, for #bladdercancer patients. Today, CG Oncology is proud to announce the Phase 2 CORE-001 study data of cretostimogene in combination with pembrolizumab for the treatment of  BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS). These positive findings, demonstrating a complete response (CR) rate of 54% (19/35) (95% CI 37-71%) in the ITT population at the 24-month landmark, will be presented in a poster abstract at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Aligning with this year’s meeting theme, “The Art and Science of Cancer Care: From Comfort to Cure,” we are eager to share our commitment to expanding treatment options for bladder cancer and highlighting the clinical benefits of cretostimogene as both a #monotherapy and in combination with other therapies. We thank everyone involved in this study for their significant contributions that are advancing new standards of cancer care. Join us at #ASCO24 from May 31 to June 4 to explore how we are transforming the treatment landscape of #NMIBC! Details of the abstract are as follows: 📄 Abstract Number: 4601 🔍 Poster Session & Primary Track: Genitourinary Cancer - Kidney and Bladder 🗓️ Date & Time: June 2, 2024, 9:00-10:00am CDT 🎤 Presenter: Roger Li, M.D., lead study investigator and Urologic Oncologist at Moffitt Cancer Center For more information, read the full release: https://bit.ly/3QZhf4T #CORE001 #ASCO #ClinicalTrials #UroOncology #CancerResearch #MedicalResearch #Therapeutics #DrugDevelopment #PatientCare #Immunotherapy #CGOncology #cretostimogene 

🏙️ Who's headed to the Windy City for #ASCO24? Join us on June 2, 2024, for the poster presentation of our Phase 2 CORE-001 final study results, evaluating cretostimogene grenadenorepvec in combination with pembrolizumab. Roger Li, M.D. and lead study investigator, will present these findings during the Poster Session, Genitourinary Cancer - Kidney and Bladder (Abstract Number: 4601), from 9:00-10:00 am CDT. Our patient-focused approach aims to transform the standard of care and allow us to address different stages of #bladdercancer. With the ongoing success of our clinical studies, we're highly encouraged by cretostimogene's potential to advance the clinical management for Non-Muscle Invasive Bladder Cancer (#NMIBC). If you are attending ASCO, our leadership team is ready to connect with you and share how we strive to bring hope to the 83,000+ people diagnosed with bladder cancer each year. 📄 See the full details of our poster presentation here: https://bit.ly/3QZhf4T #CORE001 #UroOncology #CancerResearch #ClinicalResearch #PatientCare #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #CGOncology #cretostimogene

🩺 Clinical trials are a critical component in our fight against #bladdercancer, especially for novel therapies like cretostimogene grenadenorepvec, which has the potential to be a breakthrough treatment. Dr. Robert Svatek of UT Health San Antonio highlights the importance of patient involvement in our ongoing pursuit to address the significant unmet medical needs across all stages of the disease. 🎥 Watch Dr. Svatek's insights: https://lnkd.in/gDp6ncXt Non-Muscle Invasive Bladder Cancer (#NMIBC) accounts for 75% of newly diagnosed bladder cancer diagnoses. CG Oncology is actively enrolling eligible participants and recruiting interested sites for the PIVOT-006 study. This Phase 3, open-label, randomized trial is designed to explore the potential of cretostimogene for NMIBC. In honor of global #ClinicalTrialsDay, take a moment to learn more about the PIVOT-006 Clinical Study: 🔎 ClinicalTrials.gov ID: NCT06111235 📧 Contact: [email protected]  💻 Visit: CGOncology.com/PIVOT-006 🎗️ Find additional support resources at the Bladder Cancer Advocacy Network website at https://bcan.org. #ClinicalTrials #UrothelialCancer #CancerResearch #MedicalResearch #Urology #Immunotherapy #Therapeutics #BCAN #CGOncology #PIVOT006 #cretostimogene

👏 Thank you to the Bladder Cancer Advocacy Network (#BCAN) and everyone who joined us in the 2024 Walk to End Bladder Cancer! It was a privilege to come together across the nation and share our commitment to advancing #bladdercancer research. While our CG Oncology Teams in #Seattle, #SanDiego, and #Austin crossed the finish line earlier today, the fight against bladder cancer isn’t slowing down. Every step taken significantly benefits patients and their loved ones. Please continue to support BCAN’s mission by participating in a virtual walk to accelerate research for a cure. 👉 Discover how you can get involved here: bit.ly/3x65qD3 #EndBladderCancer #BladderCancerAwareness #UroOncology #CancerResearch #CancerSupport #CGOncology #BCANWalk

Tomorrow is the day! Our final group gathering for the Bladder Cancer Advocacy Network (#BCAN) 2024 Walk to End Bladder Cancer is this Saturday, May 18th! Bladder cancer ranks as the 7th most common cancer globally and the 4th most common in men. Please consider joining us to raise awareness and take steps towards finding a cure. Participate with CG Oncology in one of the following cities or join the virtual walk from any location throughout this month. 📍 Austin Team: https://bit.ly/BCANWalkATX 📍 San Diego Team: https://bit.ly/BCANWalkSD 📍 Seattle Team: https://bit.ly/BCANWalkSEA  🌐  Virtual Walk: https://lnkd.in/gPSkNv29 Together, we can advance research and give hope in the fight against #bladdercancer. See you there! 🚶♀️🚶 #BladderCancerAwareness #EndBladderCancer #UroOncology #CancerResearch #CancerSupport #CGOncology #BCANWalk

🔬 Learn more about the PIVOT-006 Phase 3 randomized clinical trial that explores the potential of cretostimogene for patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (#NMIBC). In this informational video, Dr. Robert Svatek of UT Health San Antonio outlines the open label trial and shares how patients can find more information about the PIVOT-006 study eligibility. 🎥 Watch the informative video here: https://lnkd.in/eDRsXnD8 It is a privilege to collaborate with colleagues like Dr. Svatek and organizations such as the Bladder Cancer Advocacy Network (#BCAN) that share our commitment of advancing #bladdercancer research and improving treatment options for patients following #TURBT. By sharing this post, you are contributing to the support system for those affected and advancing the treatment landscape for NMIBC. 🔎 ClinicalTrials.gov ID: NCT06111235 📧 Contact: [email protected]  💻 Visit: CGOncology.com/PIVOT-006 🎗️ For more support resources, visit the BCAN website at https://bcan.org. #ClinicalTrials #UrothelialCancer #CancerResearch #MedicalResearch #Urology #Immunotherapy #Therapeutics #BCAN #CGOncology #PIVOT006 #cretostimogene

This year, more than 83,000 people will receive a diagnosis of #BladderCancer, with 75% of these new cases being Non-Muscle-Invasive Bladder Cancer (#NMIBC). Driven by and for patients, CG Oncology is committed to changing the treatment paradigm and addressing unmet patient needs. This #BladderCancerAwarenessMonth, join us in supporting those impacted by participating in the Bladder Cancer Advocacy Network (#BCAN) 2024 Walk to End Bladder Cancer. Every step you take makes a difference by spreading awareness and advancing research. We encourage you to sign up with a CG Oncology Team in select cities or virtually at bit.ly/3x65qD3 🚶♀️🚶♂️ #BladderCancerAwareness #EndBladderCancer #UroOncology #CancerResearch #CancerSupport #CGOncology #BCANWalk

What an incredible experience at 2024 American Urological Association (AUA) Annual Meeting in #SanAntonioTX! Our team had a wonderful time connecting with colleagues, sharing our research, and presenting our latest investigational data on cretostimogene grenadenorepvec. We extend a sincere thank you to all who visited us in booth #100 and are already looking forward to next year! For those we missed, we welcome you to reach out to CG Oncology’s Medical Affairs at [email protected] to discover how our solutions and clinical trial programs may fit with your practice. Visit us at CGOncology.com for more information. 💪 The fight against #bladdercancer continues! See you at #AUA25! #CGOncology #UroOncology #CancerResearch #MedicalResearch #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #cretostimogene #AUA24

CG Oncology is at the forefront of developing transformative technology in the fight against #bladdercancer. Our commitment to delivering the next wave of innovation was highlighted this weekend at the 2024 American Urological Association (AUA) Annual Meeting, where the promising Phase 3 BOND-003 study (NCT04452591) results were presented by Mark Tyson, M.D., M.P.H. Ambaw Bellete, our President and COO, shared with BioSpace’s Tristan Cesar Mañalac that these interim findings reinforce cretostimogene’s “potential as a bladder-sparing therapeutic that could materially improve both patient outcomes and quality of life” in patients with Non-Muscle Invasive Bladder Cancer (#NMIBC). 📄 Learn more about our clinical trial data and its positive impact on shaping the future of NMIBC treatment:

It was a full house at the #AUA2024 "Clinical Trials in Progress, Bladder Cancer" session, featuring oral presentations by Robert Svatek, MD on the PIVOT-006 study and Mark Tyson, M.D., M.P.H on the BOND-003- Cohort P study that address the significant unmet patient needs for treating the disease. Cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy being evaluated in both ongoing clinical trials. The insights shared reinforce our commitment to improving outcomes for patients and transforming the standard of care. If you're attending the American Urological Association (AUA) Annual meeting, come join us in booth #100 to meet our Medical Team and learn more about our advances in #bladdercancer! 🤝 #BOND003 #PIVOT006 #ClinicalTrial #UroOncology #Therapeutics #CancerResearch #MedicalResearch #DrugDevelopment #Immunotherapy #cretostimogene #CGOncology